Kenji Fukunaga

This inventor holds 18 USPTO granted patents and 4 EPO patents, primarily in Heterocyclic Compounds. Top assignees: Mitsubishi Tanabe Pharma Corporation, Fujitsu Corporation, Sanofi-Aventis. Active years: 2000-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kenji Fukunaga. Retrieved from https://idiyas.com/inventor/kenji-fukunaga

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 18

% Patents Active = 38.9

EPO Patents = 4 (Patent Applications = 3)

Average Co-Inventor Count = 5.0

ph-index = 6

Forward Citations = 259(Granted Patents)

Location History:

Yokohama, JP (2006)
Kawasaki, JP (2010 - 2011)
Tokyo, JP (2005 - 2012)
Kanagawa, JP (2009 - 2013)
Kobe, JP (2017)
Osaka, JP (2000 - 2020)

Company Filing History:

9 out of 263

Mitsubishi Tanabe Pharma Corporation

Mitsubishi Pharma Corporation

patents

where one patent can have more than one assignee

Years Active: 2000-2020

Loading Chart...

Areas of Expertise:

Bicyclic Compounds

Tricyclic Compounds

Heterocyclic Derivatives

Tau Protein Kinase Inhibitors

Demultiplexing Device

Communication Apparatus

Packet Transmission

Data Output Apparatus

Pharmaceutical Use

Transmission Line

Data Discard Functions

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10793582 - Bicyclic heterocyclic compound (2020-10-06),

2. 10065972 - Bicyclic or tricyclic heterocyclic compound (2018-09-04),

3. 9735906 - Demultiplexing device and multiplexing device (2017-08-15),

4. 8592417 - 2-substituted-6-heterocyclic pyrimidone derivatives as tau protein kinase 1 inhibitors (2013-11-26),

5. 8569294 - 2-(cyclic amino)-pyrimidone derivatives (2013-10-29),

6. 8518939 - 6-pyrimidinyl-pyrimid-4-one derivative (2013-08-27),

7. 8198437 - 6-pyrimidinyl-pyrimid-4-one derivative (2012-06-12),

8. 8129377 - 6-(pyridinyl)-4-pyrimidone derivates as tau protein kinase 1 inhibitors (2012-03-06),

9. 8106045 - 2-morpholino-4-pyrimidone compound (2012-01-31),

10. 8086770 - Communication apparatus with data discard functions and control method therefor (2011-12-27),

11. 7907632 - Data output apparatus, communication apparatus and switch apparatus (2011-03-15),

12. 7706391 - Packet transmission method and device (2010-04-27),

13. 7504411 - 2,3,6-Trisubstituted-4-pyrimidone derivatives (2009-03-17),

14. 7359316 - Reception pointer processing apparatus in SDH transmission system (2008-04-15),

15. 7027459 - Transmission line terminating apparatus that performs packet processing (2006-04-11),

Title: Kenji Fukunaga: Innovator in Heterocyclic Compounds

Introduction

Kenji Fukunaga is a prominent inventor based in Osaka, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of novel compounds. With a total of 18 patents to his name, Fukunaga's work has had a substantial impact on medicinal chemistry.

Latest Patents

Fukunaga's latest patents include a bicyclic heterocyclic compound that exhibits superior inhibitory action on KAT-II. This invention provides a novel compound, a production method, and a pharmaceutical composition containing the compound. Additionally, he has developed a bicyclic or tricyclic heterocyclic compound represented by a specific formula, which includes an optionally substituted aromatic group.

Career Highlights

Throughout his career, Kenji Fukunaga has worked with notable companies such as Mitsubishi Tanabe Pharma Corporation and Fujitsu Corporation. His expertise in the field has allowed him to contribute to various innovative projects and advancements in pharmaceutical research.

Collaborations

Fukunaga has collaborated with esteemed colleagues, including Kazutoshi Watanabe and Toshiyuki Kohara. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Kenji Fukunaga's contributions to the field of heterocyclic compounds and pharmaceuticals highlight his role as a leading inventor. His work continues to influence the development of new therapeutic agents, showcasing the importance of innovation in medicine.

Profile summary based on public USPTO records.